Health related quality of life for multiple myeloma patients according to treatment strategy after autologous stem cell transplant: a cross-sectional study using EORTC, EQ-5D and MY-20 scales
Jason Tay(University of Ottawa), Arleigh McCurdy(University of Ottawa), Francis K. Buadi, Darrell White(Dalhousie University), Robert Wood(University of Wisconsin–Madison), Ravi Vij(Washington University in St. Louis), Faiza Zafar, Jenna Roberts(Adelphi Group (United Kingdom)), Adriana Rossi(Icahn School of Medicine at Mount Sinai), Kim Newhouse, Sophee Blanthorn-Hazell(Adelphi Group (United Kingdom)), Sujith Dhanasiri(Bristol-Myers Squibb (Switzerland)), Tamila L. Kindwall‐Keller(MetroHealth Medical Center), Maxim Norkin(Centre Hospitalier Universitaire Vaudois)
Cited by 10
Related Papers
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
|Cancer Cell|2014|1k
<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
|New England Journal of Medicine|2016|783
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|New England Journal of Medicine|2023|695